At baseline, one group of patients (intervention group) received individualized, tailored education towards the knowledge gaps revealed by the JAKQ. The other group (control group) received standard care. Both at baseline and after 1 month, patients had to complete 3 questionnaires to assess the knowledge level (JAKQ), the symptom profile (Leuven Arrhythmia Questionnaire) and the quality of life (SF-12 questionnaire).

Results The 1 month follow-up was completed in 64 patients (i.e. drop-out of 4.5%) of whom 31 were assigned to the intervention group and 33 to the control group. Patients had a mean age of 72 ± 8 years and 61.1% were male. The completion of the JAKQ took on average 6.2 ± 2.9 min (n = 64) at baseline and 6.4 ± 2.8 min at follow-up (n = 64). Providing tailored education after JAKQ completion in the intervention group required an extra 8.5 ± 4.9 min (n = 31). When re-assessed 1 month later, the intervention group scored significantly better on the JAKQ compared to baseline (58.5 ± 15.9% vs. 77.4 ± 13.3%, P < 0.001), while there was no improvement in the control group (59.1 ± 18.5% vs. 61.6 ± 19.6%, P = 0.428). No significant effects on symptom profile or quality of life could be found after 1 month.

Conclusions The JAKQ is a suitable tool to provide individualized education for AF patients. After a single directed educational session based on completion of the JAKQ, the knowledge level of AF patients could be significantly improved with lasting effects after one month. This small pilot study with short follow-up did not show impact on symptom burden or quality of life, which may need larger and longer-term studies.

The “Health Buddies” application: a novel way to improve the medication adherence and knowledge of atrial fibrillation patients. — L. Desteghe, K. Kluts, J. Vijgen, D. Dilling-Boer, K. Koopman, J. Schurmans, P. Dendale, H. Heidbuchel (1Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium; 2Heart Center, Jessa Hospital, Hasselt, Belgium).

Objectives Optimal thromboembolic prevention in atrial fibrillation (AF) patients requires strict adherence to the prescribed oral anticoagulation treatment. The ‘Health Buddies’ application was developed for AF patients to improve their adherence to non-vitamin K antagonist oral anticoagulants (NOACs) by arranging a virtual contract with their grandchild(ren) providing daily challenges for both. This innovative tool educates, reminds, motivates and supports AF patients to be adherent. This pilot study assessed the feasibility and usability of the ‘Health Buddies’ application in a large target group of AF patients.

Methods The feasibility of the app (developed by i-propeller and DAE Studios with a grant from Bayer NV) was investigated by assessing the number of eligible AF patients (based on current prescription of NOACs; the presence of grandchildren between 5 and 15 years old; availability of a smartphone, computer or tablet), and the proportion of those willing to participate. Participants had to use the application for 3 months. We examined the motivation of the patients and grandchildren to use the application (based on the number of logins to the app), and their perception of its usefulness by specific questionnaires.

Results Out of 830 screened AF patients, 114 were eligible for inclusion. In total, 420 patients (58.7%) were excluded because they were not taking NOACs. Of the remaining 410 NOAC patients, 228 had no grandchildren in the correct age category (50.6%), 43 had no smartphone, computer or tablet (10.5%) and 25 patients (6.1%) were excluded for other reasons. Only 13.2% of the eligible patients (n = 15) was willing to participate in the study. Main reasons cited for not participating were: no interest to participate in general or in the concept in particular (29.3%), not feeling comfortable using technology (22.2%), no interest by the grandchildren or their parents (20.2%), or too busy lifestyle (12.1%). The proportion of days logged-in into the application ranged between 1.1% and 98.9% for patients and between 5.6% and 80.0% for the grandchildren. App use by the grandchildren decreased towards the end of the study period (P < 0.001). The application scored positive on clearness and novelty as measured with the user experience questionnaire.

Conclusions Only a small proportion of the current AF population seems eligible for this innovative application in its current form. Although perceived as novel by the users, a large subset of patients was not willing to participate in this study or to use the application. Adaptations are needed to expand the target group in the future.

Late potentials are more pronounced in SCNSA mutation carriers compared to SCNSA negative Brugada syndrome patients. — T. Robyns, B. Vandenberk, J. Ector, C. Garweg, A. Corveleyn, C. Kuiperi, J. Breckpot, D. Nuyens, R. Willems (1Department of Cardiovascular Diseases, University hospitals Leuven, Belgium; 2Department of Cardiovascular Sciences, University of Leuven, Belgium; 3Center for Human Genetics, University hospitals Leuven, Belgium; 4Department of Cardiology, Ziekenhuis Oost Limburg Genk, Belgium).

Objective Mutations in the SCNSA gene are the main monogenetic cause of Brugada syndrome and are found in about 25% of patients. Typically SCNSA mutations cause both atrial and ventricular conduction slowing, while these findings are not (or to a lesser extent) observed in SCNSA negative BrS patients. Therefore we evaluated whether late potentials (LP) as assessed by SAECG are more prevalent